Evidence map›Paper›PMID 38546952›Full record

ArticleIrish journal of medical science2024

Are systematic prostate biopsy still necessary in biopsy naive men?

Matthew Chau, Mitchell Barns, Owain Barratt, Kara McDermott, Melvyn Kuan, Patrick Teloken

Abstract read
PubMed Publisher
In one paragraph

Article in Irish journal of medical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Matthew ChauDepartment of Urology, Sir Charles Gairdner Hospital, Perth, Australia. matthew.chau@health.wa.gov.au.ORCID http://orcid.org/0000-0002-3317-212X
Mitchell BarnsDepartment of Urology, Sir Charles Gairdner Hospital, Perth, Australia.
Owain BarrattDepartment of Urology, Sir Charles Gairdner Hospital, Perth, Australia.
Kara McDermottDepartment of Urology, Sir Charles Gairdner Hospital, Perth, Australia.
Melvyn KuanDepartment of Urology, Sir Charles Gairdner Hospital, Perth, Australia.
Patrick TelokenDepartment of Urology, Sir Charles Gairdner Hospital, Perth, Australia.
Sir Charles Gairdner Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMultiparametric MRI and the transperineal approach have become standard in the diagnostic pathway for suspected prostate cancer. Targeting of MRI lesions is performed at most centers, but the routine use of systematic cores is controversial. We aim to assess the value of obtaining systematic cores in patients undergoing cognitive fusion targeted double-freehand transperineal prostate biopsy. MATERIALS AND

methodsPatients who underwent a cognitive fusion, freehand TPB at a single tertiary urology service (Perth, Australia) between November 2020 and November 2021 were retrospectively reviewed. Patients were included if they were biopsy naive and had a clinical suspicion of prostate cancer, based on their mpMRI results. Both targeted and systematic cores were taken at the time of their biopsy.

resultsOne hundred forty patients suited the selection criteria. Clinically significant cancer was identified in 63% of patients. Of those that had clinically significant cancer, the target lesion identified 91% of the disease, missing 9% of patients whom the target biopsy detected non-clinically significant cancer but was identified in the systematic cores. Higher PI-RADS category patients were also found to be associated with an increasing likelihood of identifying clinically significant cancer within the target.

conclusionsIn patients with PI-RADS 3 and higher, the target biopsy can miss up to 9% of clinically significant cancer. Systematic cores can add value as they can also change management by identifying a high-risk disease where only intermediate cancer was identified in the target. A combination of targeted and systematic cores is still required to detect cancer.

Indexed as

ProstateProstatic NeoplasmsAgedHumansImage-Guided BiopsyMaleMiddle AgedMultiparametric Magnetic Resonance ImagingRetrospective StudiesBiopsyProstate cancerSystematic biopsyTarget biopsy

Identifiers

PMID38546952
OpenAlexW4393260629

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.